{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ribociclib&page=11", "query": { "intervention": "ribociclib", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 138, "total_pages": 14, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ribociclib&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ribociclib&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-18T00:12:56.917Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02154776", "title": "Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Breast Cancer" ], "interventions": [ { "name": "LEE011", "type": "DRUG" }, { "name": "Buparlisib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 13, "start_date": "2014-06-27", "completion_date": "2016-10-26", "has_results": false, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-10-18T00:12:56.917Z", "location_count": 5, "location_summary": "Los Angeles, California • Lafayette, Indiana • Charleston, South Carolina + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "Charleston", "state": "South Carolina" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT02154776" }, { "nct_id": "NCT06065748", "title": "A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer" ], "interventions": [ { "name": "Giredestrant", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "LHRH Agonist", "type": "DRUG" }, { "name": "FoundationOne Liquid CDx Assay (F1LCDx)", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1050, "start_date": "2023-12-11", "completion_date": "2029-02-12", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-18T00:12:56.917Z", "location_count": 40, "location_summary": "Daphne, Alabama • Greenbrae, California • Harbor City, California + 34 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Greenbrae", "state": "California" }, { "city": "Harbor City", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06065748" }, { "nct_id": "NCT05238922", "title": "Study of INCB123667 in Subjects With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "INCB0123667", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 291, "start_date": "2022-07-05", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-10-18T00:12:56.917Z", "location_count": 18, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05238922" }, { "nct_id": "NCT05683418", "title": "A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HR+/HER2-negative Breast Cancer" ], "interventions": [ { "name": "TOS-358", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Totus Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 241, "start_date": "2023-02-15", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-10-18T00:12:56.917Z", "location_count": 9, "location_summary": "Chicago, Illinois • Boston, Massachusetts • Las Vegas, Nevada + 4 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05683418" }, { "nct_id": "NCT02494921", "title": "LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Docetaxel-PNP", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rahul Aggarwal", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 43, "start_date": "2015-11-20", "completion_date": "2021-07-30", "has_results": true, "last_update_posted_date": "2022-08-31", "last_synced_at": "2026-10-18T00:12:56.917Z", "location_count": 6, "location_summary": "San Francisco, California • Chicago, Illinois • Ann Arbor, Michigan + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02494921" }, { "nct_id": "NCT06377852", "title": "The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Palbociclib 125mg", "type": "DRUG" }, { "name": "Ribociclib 600mg", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "American Society of Clinical Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 500, "start_date": "2024-10-29", "completion_date": "2028-09-01", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-18T00:12:56.917Z", "location_count": 88, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 76 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06377852" }, { "nct_id": "NCT02420691", "title": "Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Digestive System Neuroendocrine Neoplasm", "Duodenal Neuroendocrine Tumor G1", "Functional Pancreatic Neuroendocrine Tumor", "Gastric Neuroendocrine Tumor", "Intermediate Grade Lung Neuroendocrine Neoplasm", "Low Grade Lung Neuroendocrine Neoplasm", "Nonfunctional Pancreatic Neuroendocrine Tumor", "Thymus Neoplasm" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Ribociclib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2015-08-25", "completion_date": "2019-06-05", "has_results": true, "last_update_posted_date": "2020-10-30", "last_synced_at": "2026-10-18T00:12:56.917Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02420691" }, { "nct_id": "NCT01820364", "title": "LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "LGX818", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Array BioPharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2013-11", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2017-01-09", "last_synced_at": "2026-10-18T00:12:56.917Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01820364" }, { "nct_id": "NCT06062498", "title": "Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen-receptor-positive Breast Cancer", "HER2/Neu-Negative Breast Cancer", "Advanced Breast Cancerv", "Metastatic Breast Cancer" ], "interventions": [ { "name": "elacestrant, palbociclib, abemaciclib, ribociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 174, "start_date": "2023-09-29", "completion_date": "2029-07-01", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-18T00:12:56.917Z", "location_count": 3, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06062498" }, { "nct_id": "NCT02732119", "title": "Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": "2016-06-14", "completion_date": "2020-02-25", "has_results": true, "last_update_posted_date": "2021-05-05", "last_synced_at": "2026-10-18T00:12:56.917Z", "location_count": 25, "location_summary": "Chandler, Arizona • Fayetteville, Arkansas • Los Angeles, California + 20 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Maria", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02732119" } ] }